Literature DB >> 18566319

Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy.

Judith S Currier, Jens D Lundgren, Andrew Carr, Daniel Klein, Caroline A Sabin, Paul E Sax, Jeffrey T Schouten, Marek Smieja.   

Abstract

Entities:  

Mesh：

Year:  2008        PMID： 18566319      PMCID： PMC5153327          DOI： 10.1161/CIRCULATIONAHA.107.189624

Source DB:  PubMed          Journal:  Circulation        ISSN： 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  42 in total

1.  Premature atherosclerosis in HIV-infected individuals--focus on protease inhibitor therapy.

Authors:  M Depairon; S Chessex; P Sudre; N Rodondi; N Doser; J P Chave; W Riesen; P Nicod; R Darioli; A Telenti; V Mooser
Journal:  AIDS       Date:  2001-02-16       Impact factor: 4.177

2.  The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

Authors:  M G Law; N Friis-Møller; W M El-Sadr; R Weber; P Reiss; A D'Arminio Monforte; R Thiébaut; L Morfeldt; S De Wit; C Pradier; G Calvo; O Kirk; C A Sabin; A N Phillips; J D Lundgren
Journal:  HIV Med       Date:  2006-05       Impact factor: 3.180

3.  Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients. Part II: gender differences.

Authors:  Till Neumann; T Woiwod; A Neumann; B Ross; C Von Birgelen; L Volbracht; Norbert H Brockmeyer; G Gerken; R Erbel
Journal:  Eur J Med Res       Date:  2004-02-27       Impact factor: 2.175

4.  Subclinical carotid atherosclerosis in HIV-infected patients: role of combination antiretroviral therapy.

Authors:  Carlos Jericó; Hernando Knobel; Nahum Calvo; María L Sorli; Ana Guelar; Juan L Gimeno-Bayón; Pere Saballs; José L López-Colomés; Juan Pedro-Botet
Journal:  Stroke       Date:  2006-01-26       Impact factor: 7.914

5.  Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study).

Authors:  Luc de Saint Martin; Olivier Vandhuick; Philippe Guillo; Véronique Bellein; Luc Bressollette; Nathalie Roudaut; Antonio Amaral; Elisabeth Pasquier
Journal:  Atherosclerosis       Date:  2005-08-30       Impact factor: 5.162

6.  Protease inhibitor exposure and increased risk of cardiovascular disease in HIV-infected patients.

Authors:  U H Iloeje; Y Yuan; G L'italien; J Mauskopf; S D Holmberg; A C Moorman; K C Wood; R D Moore
Journal:  HIV Med       Date:  2005-01       Impact factor: 3.180

7.  Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection.

Authors:  Samuel A Bozzette; Christopher F Ake; Henry K Tam; Sophia W Chang; Thomas A Louis
Journal:  N Engl J Med       Date:  2003-02-20       Impact factor: 91.245

8.  Coronary heart disease in HIV-infected individuals.

Authors:  Judith S Currier; Anne Taylor; Felicity Boyd; Christopher M Dezii; Hugh Kawabata; Beth Burtcel; Jen-Fue Maa; Sally Hodder
Journal:  J Acquir Immune Defic Syndr       Date:  2003-08-01       Impact factor: 3.731

9.  Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients.

Authors:  Jeroen P H van Wijk; Eelco J P de Koning; Manuel Castro Cabezas; Jorge Joven; Jos op't Roodt; Ton J Rabelink; Andy M Hoepelman
Journal:  J Am Coll Cardiol       Date:  2006-02-23       Impact factor: 24.094

10.  Class of antiretroviral drugs and the risk of myocardial infarction.

Authors:  Nina Friis-Møller; Peter Reiss; Caroline A Sabin; Rainer Weber; Antonella d'Arminio Monforte; Wafaa El-Sadr; Rodolphe Thiébaut; Stephane De Wit; Ole Kirk; Eric Fontas; Matthew G Law; Andrew Phillips; Jens D Lundgren
Journal:  N Engl J Med       Date:  2007-04-26       Impact factor: 91.245
View more
  145 in total

1.  Progress in prevention: improving cardiovascular risk management among human immunodeficiency virus-positive individuals.

Authors:  Jason E Farley; Carrie Tudor; Cheryl R Dennison
Journal:  J Cardiovasc Nurs       Date:  2010 Jul-Aug       Impact factor: 2.083

2.  Smoking and projected cardiovascular risk in an HIV-positive Asian regional cohort.

Authors:  T C Do; D Boettiger; M Law; S Pujari; F Zhang; R Chaiwarith; S Kiertiburanakul; M P Lee; R Ditangco; W W Wong; K V Nguyen; T P Merati; T T Pham; A Kamarulzaman; S Oka; E Yunihastuti; N Kumarasamy; P Kantipong; J Y Choi; O T Ng; N Durier; K Ruxrungtham
Journal:  HIV Med       Date:  2016-08       Impact factor: 3.180

3.  MicroRNA biomarkers associated with type 1 myocardial infarction in HIV-positive individuals.

Authors:  Neal Yuan; Rebecca Scherzer; Kahraman Tanriverdi; Jeffrey Martin; Smruti Rahalkar; Priscilla Hsue
Journal:  AIDS       Date:  2019-12-01       Impact factor: 4.177

4.  Association Between Bilirubin, Atazanavir, and Cardiovascular Disease Events Among People Living With HIV Across the United States.

Authors:  Heidi M Crane; Robin M Nance; Susan R Heckbert; Corey Ritchings; Lisa Rosenblatt; Matthew Budoff; Brian R Wood; David L Tirschwell; H Nina Kim; William C Mathews; Elvin Geng; Richard D Moore; Peter W Hunt; Joseph J Eron; Greer A Burkholder; Daniel R Drozd; Felicia C Chow; Kyra J Becker; Joseph R Zunt; Emily L Ho; Rizwan Kalani; Andrew Huffer; Bridget M Whitney; Michael S Saag; Mari M Kitahata; Joseph A C Delaney
Journal:  J Acquir Immune Defic Syndr       Date:  2019-08-15       Impact factor: 3.731

5.  Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Authors:  Jesper F Højen; Thomas A Rasmussen; Karen Lise D Andersen; Anni A Winckelmann; Rune R Laursen; Jesper D Gunst; Holger J Møller; Mayumi Fujita; Lars Østergaard; Ole S Søgaard; Charles A Dinarello; Martin Tolstrup
Journal:  Mol Med       Date:  2015-04-14       Impact factor: 6.354

6.  Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES.

Authors:  Benjamin Young; Kathleen E Squires; Lisa L Ross; Lizette Santiago; Louis M Sloan; Henry H Zhao; Brian C Wine; Gary E Pakes; David A Margolis; Mark S Shaefer
Journal:  AIDS Res Hum Retroviruses       Date:  2012-12-05       Impact factor: 2.205

7.  Elevated numbers of CD163+ macrophages in hearts of simian immunodeficiency virus-infected monkeys correlate with cardiac pathology and fibrosis.

Authors:  Joshua A Walker; Megan L Sulciner; Katherine D Nowicki; Andrew D Miller; Tricia H Burdo; Kenneth C Williams
Journal:  AIDS Res Hum Retroviruses       Date:  2014-03-11       Impact factor: 2.205

8.  A genome-wide association study of carotid atherosclerosis in HIV-infected men.

Authors:  Sadeep Shrestha; Marguerite R Irvin; Kent D Taylor; Howard W Wiener; Nicholas M Pajewski; Talin Haritunians; Joseph A C Delaney; Morris Schambelan; Joseph F Polak; Donna K Arnett; Yii-Der Ida Chen; Carl Grunfeld
Journal:  AIDS       Date:  2010-02-20       Impact factor: 4.177

Review 9.  The macrophage: the intersection between HIV infection and atherosclerosis.

Authors:  Suzanne M Crowe; Clare L V Westhorpe; Nigora Mukhamedova; Anthony Jaworowski; Dmitri Sviridov; Michael Bukrinsky
Journal:  J Leukoc Biol       Date:  2009-12-01       Impact factor: 4.962

10.  Epicardial fat is associated with duration of antiretroviral therapy and coronary atherosclerosis.

Authors:  Michael Brener; Kerunne Ketlogetswe; Matthew Budoff; Lisa P Jacobson; Xiuhong Li; Panteha Rezaeian; Aryabod Razipour; Frank J Palella; Lawrence Kingsley; Mallory D Witt; Richard T George; Wendy S Post
Journal:  AIDS       Date:  2014-07-17       Impact factor: 4.177
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.